PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Julia Murk

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 4, 2026 · JOURNAL ARTICLE

Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced oral cancer—a monocentric experience

Cancer Immunology Immunotherapy

Single-center cohort of six patients from a prematurely terminated phase 2 trial with descriptive analysis only; feasibility and immune remodeling demonstrated but efficacy and safety conclusions explicitly limited by sample size and trial discontinuation.

PreliminaryFabienne Lange Leah Trumet Nonmelanoma Skin Cancer Studies

Reported

Sample size6

Median age63 years

Median follow-up81 weeks

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support